These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29112189)

  • 1. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.
    Hafner M; Heiser LM; Williams EH; Niepel M; Wang NJ; Korkola JE; Gray JW; Sorger PK
    Sci Data; 2017 Nov; 4():170166. PubMed ID: 29112189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRcalculator: an online tool for calculating and mining dose-response data.
    Clark NA; Hafner M; Kouril M; Williams EH; Muhlich JL; Pilarczyk M; Niepel M; Sorger PK; Medvedovic M
    BMC Cancer; 2017 Oct; 17(1):698. PubMed ID: 29065900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.
    Hafner M; Niepel M; Chung M; Sorger PK
    Nat Methods; 2016 Jun; 13(6):521-7. PubMed ID: 27135972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.
    Niepel M; Hafner M; Chung M; Sorger PK
    Curr Protoc Chem Biol; 2017 Jun; 9(2):55-74. PubMed ID: 28628199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid assessment of drug resistance of cancer cells to gefitinib and carboplatin using optical imaging.
    Luo Z; Samadzadeh KM; Nitin N
    Anal Biochem; 2016 Jul; 504():50-8. PubMed ID: 27059751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
    Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoresistance of Lung and Breast Cancer Cells Growing Under Prolonged Periods of Serum Starvation.
    Yakisich JS; Venkatadri R; Azad N; Iyer AKV
    J Cell Physiol; 2017 Aug; 232(8):2033-2043. PubMed ID: 27504932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying anti-cancer drug response related genes using an integrative analysis of transcriptomic and genomic variations with cell line-based drug perturbations.
    Sun Y; Zhang W; Chen Y; Ma Q; Wei J; Liu Q
    Oncotarget; 2016 Feb; 7(8):9404-19. PubMed ID: 26824188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
    Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
    Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metrics other than potency reveal systematic variation in responses to cancer drugs.
    Fallahi-Sichani M; Honarnejad S; Heiser LM; Gray JW; Sorger PK
    Nat Chem Biol; 2013 Nov; 9(11):708-14. PubMed ID: 24013279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.
    Breslin S; O'Driscoll L
    Oncotarget; 2016 Jul; 7(29):45745-45756. PubMed ID: 27304190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
    Bessette DC; Tilch E; Seidens T; Quinn MC; Wiegmans AP; Shi W; Cocciardi S; McCart-Reed A; Saunus JM; Simpson PT; Grimmond SM; Lakhani SR; Khanna KK; Waddell N; Al-Ejeh F; Chenevix-Trench G
    PLoS One; 2015; 10(5):e0125232. PubMed ID: 25969993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.
    Zhang SR; Xu YS; Jin E; Zhu LC; Xia B; Chen XF; Li FZ; Ma SL
    Acta Pharmacol Sin; 2017 Jan; 38(1):100-109. PubMed ID: 27840409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD44hiCD24lo mammosphere-forming cells from primary breast cancer display resistance to multiple chemotherapeutic drugs.
    Ji P; Zhang Y; Wang SJ; Ge HL; Zhao GP; Xu YC; Wang Y
    Oncol Rep; 2016 Jun; 35(6):3293-302. PubMed ID: 27109463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.
    Arteaga CL; Forseth BJ; Clark GM; Von Hoff DD
    Cancer Res; 1987 Dec; 47(23):6248-53. PubMed ID: 3119196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status.
    Bracht K; Kiefer T; Dölken G; Bednarski PJ
    J Cancer Res Clin Oncol; 2007 Dec; 133(12):957-67. PubMed ID: 17562080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.